Rechercher dans ce blog

Wednesday, April 20, 2022

The National Fight Against COVID-19 Isn’t Ready To Go To The Sewers - FiveThirtyEight

As COVID-19 testing sites close and experts warn that case numbers are capturing a small minority of infections, many public health experts are turning to a newer source that might tell us what’s going on with the virus: our poop.

In the past two years, scientists have developed systems that can detect COVID-19 in our wastewater. This is a great early warning system, since the virus can show up in people’s waste days before they begin to experience symptoms or are able to get tested. It’s also less biased than case data: Not everyone can find a COVID-19 test and not every positive result will get reported … but everybody poops.

As with so many other COVID-19 metrics, however, interpreting wastewater data is not as simple as it seems. Before COVID-19, this type of data hadn’t been used to track respiratory viruses. This means the Centers for Disease Control and Prevention has little established infrastructure to build upon. The agency is attempting to standardize reporting from researchers across the country, many of whom have different water sampling methods. Plus, the state and local health officials who cite wastewater as a potential replacement for underreported case numbers aren’t used to interpreting data from the environment, which has unique caveats and requires a learning curve for those used to looking at numbers from hospitals and health clinics.

The Documenting COVID-19 project surveyed 19 state and local health agencies, as well as scientists who work on wastewater sampling, to learn about the challenges they’re facing. We found that many states are months away, if not longer, from being able to use wastewater data to guide public health decisions, even as the rise of an omicron subvariant, BA.2, looms. Meanwhile, the CDC’s highly shared wastewater surveillance dashboard is a work in progress, and is difficult to interpret for users who might hope to follow the trends in their areas.


“People are saying, ‘We can’t trust the [PCR] testing data now,’” and shifting to rely more on data from wastewater, said Steve Balogh, research scientist at the Metropolitan Council, a local agency in the Twin Cities, Minnesota, metro area that started wastewater surveillance in late 2020.

But health departments can’t just flick a switch — or gaze into the bottom of a toilet bowl — and suddenly get comprehensive COVID-19 trends from wastewater. It takes time to set up sampling technology, understand the environment around a wastewater site and collect enough data for trends to be easily interpretable.

Some universities and their public health partners in California began investing in wastewater surveillance early in the pandemic. San Diego, for example, began wastewater sampling in fall 2020 as part of the campus reopening efforts for the University of California, San Diego, said Smruthi Karthikeyan, a postdoctoral researcher who works on the surveillance. It was later expanded to other parts of the city, including sites chosen to monitor COVID-19 at local public school districts.

Karthikeyan’s team uses machines called “autosamplers,” which are placed inside a sewage system and programmed to collect small volumes of water over time. These machines slowly collect a set amount of water over the course of 24 hours, which is a more thorough method than grabbing that volume all at once since it captures waste from the entire day. Researchers will then typically take a small portion of the wastewater, dilute it with other chemicals to preserve genetic material in the sample and run COVID-19 PCR tests to determine whether the virus is present. They might also run tests to look for specific variants, like omicron. Karthikeyan’s team uses robots to automate these analysis steps and cut down on errors; other researchers have more human-driven processes.

UCSD now processes about 200 wastewater samples daily, Karthikeyan said. When signs of COVID-19 show up in the wastewater for a particular site, another automated system alerts residents or workers of that site that they should get a PCR test. These alerts help contain outbreaks on UCSD’s campus while minimizing testing costs.

People who receive the alerts “feel like they have a reason to get tested,” Karthikeyan said. “And we get 98 percent compliance when we send out these emails to students.” Other colleges and universities have similarly used wastewater to drive targeted testing.

The San Diego wastewater surveillance network also directs COVID-19 precautions at the UCSD Health system, with tiered guidance based on wastewater data (and a couple of other metrics) telling workers when they need to mask, reduce their in-person work hours or take other precautions. In March, just one week after the health system started using this guidance, wastewater trends prompted a return to mandatory masking.

But many places don’t have the same resources to set up wastewater surveillance — or peg public health actions to data — as San Diego does. When asked if he knew of other institutions using wastewater to guide their safety measures, UCSD Health chief medical officer Dr. Christopher Longhurst said no: “I couldn’t point you to one.”

In recent months, scientists in California have expanded wastewater surveillance to more rural parts of the state, with support from the state’s Department of Public Health. This poses new challenges: Public health officials often aren’t used to looking at data from outside hospitals or health clinics, and there are many logistical hurdles to setting up sampling in new locations, combined with the complications of interpreting data from less populous areas, where wastewater surveillance is highly sensitive to changes in COVID-19 spread.

One document from Stanford University’s Sewer Coronavirus Alert Network (SCAN) describes how the genetic material shed by someone with COVID-19 may change: over the course of their infection, from person to person and depending on measurement techniques, the weather, an influx of spring breakers, or even local business practices. For example, Modesto — a city in California’s Central Valley — had a lot of fruit cannery waste in its sewage. This industrial flow may have blocked the signal of the coronavirus’s genetic material, impacting scientists’ ability to isolate it in PCR testing, said Colleen Naughton, an environmental engineering professor at the University of California, Merced, who works on wastewater monitoring in this region.

The Maine Center for Disease Control and Prevention has faced similar issues as it expands monitoring from Portland, the state’s major urban center, to more rural communities, said Michael Abbott, who leads wastewater screening at the agency.

One of Portland’s wastewater treatment plants has been a long-running collection site for Biobot, a wastewater monitoring company based in Cambridge, Massachusetts. In Portland, a city of almost 70,000, it takes a “really significant increase” in COVID-19 prevalence for the virus levels in sewage to begin ticking up, Abbott said. So when the wastewater goes up, the trend is easy to interpret.

But in rural parts of the state, some of which started monitoring during the omicron surge, “the data tends to bounce up and down more rather than following a fairly smooth curve,” Abbott said. Small numbers of cases may have an outsized impact on wastewater levels, particularly when those cases represent outside tourists going into tiny towns, as is common in Maine.

As public health officials learn to navigate wastewater data, several states’ public health agencies told us they don’t yet consider the system a reliable source for making policy decisions — at least not in isolation. A recent report from The Rockefeller Foundation found that many local agencies, especially those serving rural areas, don’t have the internal capacity to go all-in on wastewater data as they deal with budget cuts and burnout.

The Minnesota Department of Health is working to expand wastewater sampling, agency spokesperson Garry Bowman said in an email. But this expansion would take weeks or months to turn into useful data, long after Minnesota’s PCR testing numbers have become wholly unreliable. And even if Minnesota does expand its wastewater monitoring to cover the whole state, the agency isn’t sure if the federal government will keep up its funding, said Bowman.

It would be hard to tell these local wastewater challenges exist, though, looking at the CDC’s wastewater dashboard. Highly publicized upon its addition to the agency’s COVID Data Tracker in February, the dashboard only showed one metric until early April: colored dots representing an increase or decrease in coronavirus levels detected at each site over the past two weeks. There was no context about the virus’s actual prevalence or how recent trends compare to longer time frames.

If a site measures “virus not detected” (meaning no COVID-19) for three weeks in a row, and then measures a fairly low level of COVID-19, the CDC dashboard would show a 100 percent increase, said Zuzana Bohrerova, an environmental scientist at Ohio State University who works on Ohio’s monitoring program. A red dot on the dashboard might be a serious warning, or it might be unimportant — the CDC’s original presentation made it difficult to tell.

“I think they were trying to be simpler,” Naughton said of the CDC dashboard. “They didn’t want to release all the concentration data, since they thought that’s difficult for people to understand.”

On April 8, the agency updated this dashboard, adding new metrics and the option to click into a specific site for a chart showing wastewater trends at that location. The updates were intended to help users better understand changes in virus levels at different sites, CDC spokesperson Brian Katzowitz said. Wastewater experts who talked to me on Twitter said they were glad to see the CDC adjusting its data visualization. Still, there’s room for other improvements that would make the data more easily understandable, Katzowitz said.

Even if thousands of new wastewater collection sites are added to the U.S.’s network in the coming weeks, it will take serious investment in data analysis and communication for the country to actually use these numbers in predicting new surges. Expanding wastewater sampling can take weeks or months before the effort begins to produce usable data and it costs a lot — money agencies aren't sure the federal government will continue to provide.

Despite its challenges, experts say that wastewater monitoring has potential beyond COVID-19 — for other respiratory viruses, antimicrobial resistance, and even identifying entirely new viruses. But without continued federal support, we won’t even be able to get useful COVID-19 surveillance at a time that it’s deeply needed.


This story was published in partnership with the Documenting COVID-19 project, which is supported by Columbia University’s Brown Institute for Media Innovation and MuckRock. The project collects and shares government documents related to the COVID-19 pandemic and works on investigative journalism projects with partner newsrooms.

Adblock test (Why?)


The National Fight Against COVID-19 Isn’t Ready To Go To The Sewers - FiveThirtyEight
Read More

Quebec duck farm says it has to kill 150,000 birds, lay off 300 staff due to avian flu - Global News

A Quebec duck-farming operation says three of its facilities have been devastated by avian flu, forcing it to slaughter 150,000 birds and lay off nearly 300 employees.

It will likely take six to 12 months and possibly several million dollars to fully restore the company’s operations, Angela Anderson of Brome Lake Ducks said in an interview Wednesday.

Brome Lake Ducks announced its first case of avian flu on April 13. Anderson said the virus was detected after employees at one of its sites noticed some of the birds getting sick and contacted a veterinarian, who recommended testing.

Read more: Avian flu cases identified among flock at handful of Quebec farms

While only three of the company’s 13 sites were affected by the H5N1 virus, one of them contained all the company’s breeding stock, including 400,000 Pekin duck eggs that were ordered destroyed by the Canadian Food Inspection Agency.

Once birds that are in the pipeline at unaffected facilities are processed, the company will have to lay off staff because there will be no more ducks coming in, she said.

“Yesterday, I spent all of my day going to 11 different sites to inform almost 300 employees that they had no more jobs in four to five weeks,” Anderson said, adding that the number doesn’t include numerous tradespeople and delivery truck drivers who serve the operation.

“The situation is extremely emotional and extremely difficult.”

Veterinarian Jean-Pierre Vaillancourt of Universite de Montreal says the highly pathogenic H5N1 bird flu represents the highest-risk strain that Quebec farmers have ever faced.

Read more: Canada’s food industry making adjustments amid large bird flu outbreak

“We’ve been monitoring high-path (avian influenza) since 1959, and we’ve never had it in Quebec, so this is a first right now,” Vaillancourt said in an interview Wednesday.

Avian influenza, he added, has been present in wild birds for years but has not posed a significant risk because the level of contamination in the environment has always been low.

This strain, however, is stronger and more contagious, which means more virus is circulating, Vaillancourt said. The strain also has a longer incubation period than previous strains, leading to birds being potentially contagious for days before anyone realizes they are sick, he said.

He said the virus can enter a facility through contact with wild birds, adding that it can also be brought in on straw and litter, or even on the shoes of people who have walked near a pond where birds gather. While he said farmers shouldn’t panic, they need to be careful and implement biosecurity protocols.

Watch: Bird flu outbreak: Can humans contract the virus? Expert weighs in

Vaillancourt said that while it doesn’t pose much of a risk to humans, it’s so contagious that all animals on an infected farm need to be destroyed on-site to stop it from spreading. Left unchecked, the virus can kill half or more of the animals in a flock, he said.

Quebec’s first bird flu cases were detected in wild geese earlier this month, and several other provinces have already reported outbreaks in wild and domestic populations. As of Wednesday morning, the Canadian Food Inspection Agency had confirmed the presence of flu in four sites in Quebec, all in the Estrie region east of Montreal.

Anderson said it will not be easy restarting operations at Brome Lake Ducks, which is one of the biggest duck producers in Canada. She said insurance doesn’t cover animal mortality, adding that while there is some compensation from Canada’s food inspection agency, it doesn’t come close to covering the losses.

New animals will also have to be sourced from Europe, which is hit by its own avian flu problems.

Anderson said she’s hoping different levels of government will compensate the company for its losses and help it get back on its feet. While the company has faced other challenges, including a major fire in 2016, she said this is the biggest yet.

“Problems we can deal with, but this one is extremely difficult and the hill that we have to climb is very steep.”

Vaillancourt said climate change is likely playing a part in the evolution of deadlier viruses, because changing temperatures affect bird migrations, leading some wild birds to visit areas they had not visited before. Breeders, he said, need to be prepared for more viruses in the years to come.

“There’s a new reality, and this is not a one-year thing,” he said.

© 2022 The Canadian Press

Adblock test (Why?)


Quebec duck farm says it has to kill 150,000 birds, lay off 300 staff due to avian flu - Global News
Read More

MSF responds to new simplified WHO treatment guidelines for cryptococcal meningitis, the number two killer of people living with HIV/AIDS - World - ReliefWeb

Urgent action needed to make WHO-recommended treatment accessible to people who need it

Background:

Geneva, 20 April 2022 -- Médecins Sans Frontières/Doctors Without Borders (MSF) welcomes the updated World Health Organization (WHO) guidelines for the management of cryptococcal meningitis, an opportunistic fungal infection, which is the number two killer of people living with HIV/AIDS after tuberculosis. The guidelines endorse a simplified regimen, following the important results of the AMBITION trial, consisting of a single high dose of liposomal amphotericin B (L-AmB), combined with two weeks of flucytosine and fluconazole, as the preferred treatment option. With new WHO global targets set to reduce deaths from cryptococcal meningitis by 50% in 2025 and 90% by 2030, MSF urges all countries to urgently adopt these guidelines to save lives of people living with HIV/AIDS.

However, access to L-AmB and flucytosine remains a significant challenge in low- and middle-income countries due to a combination of factors including the drugs not being included in national guidelines and countries not submitting requests to donors such as the Global Fund and PEPFAR to fund the procurement of these lifesaving medicines.

To begin addressing the challenges of accessing L-AmB and flucytosine, governments need to update national cryptococcal meningitis clinical guidance urgently, include these medicines in funding requests from major donors, and increase screening for cryptococcal meningitis among people living with HIV. Governments need to work with pharmaceutical companies and urge them to increase production and expand registration of these medicines to meet the expected increase in demand as countries start to adapt and implement the new guidelines.

Additionally, US corporation Gilead, the main supplier of quality-assured L-AmB, has failed to deliver on its promise of providing this lifesaving medicine at the access price of $16.25 per vial to treat cryptococcal meningitis (which would allow for the inclusion of L-AmB at approximately $195 per person under the new recommended treatment protocol) as promised to 116 countries in 2018. More than three years later, Gilead has still only provided L-AmB to less than half of the eligible countries at the access price. Furthermore, Gilead has done little to expand access in terms of registration of L-AmB where it is needed most -- with registrations in only two countries in all of sub-Saharan Africa. In addition, despite multiple quality-assured generic manufacturers of flucytosine in the market, few have been registered and made available in low- and middle-income countries.

Dr Freddy Mangana, HIV-TB Medical Supervisor for MSF in the Democratic Republic of Congo:

"With timely and effective diagnosis and treatment, people living with HIV/AIDS can survive opportunistic infections like cryptococcal meningitis. We are optimistic that the new treatment regimen recommended in the WHO guidelines will be adopted quickly by countries, as it is much simpler to give, can be started immediately in some settings, is better tolerated and will hopefully lead to shorter hospital stays for many patients. However, the limited availability of quality-assured L-AmB and flucytosine means that treatment providers working in sub-Saharan Africa struggle to treat people with cryptococcal meningitis or risk treating them with suboptimal treatments when these medicines are not available. The good news is that this new regimen also uses less L-AmB and requires less monitoring, which could reduce the overall price for countries to implement as compared to the previous L-AmB regimen, if urgently adopted into national guidelines."

Jessica Burry, HIV pharmacist for MSF's Access Campaign:

"We are encouraged that the WHO guidelines now include a simplified treatment regimen for people with cryptococcal meningitis, but it's disheartening to see the persistent challenges to accessing the required medicines. This lifesaving treatment remains out of reach and unaffordable for far too many people who need it. To ensure we meet the new WHO targets for decreasing deaths from cryptococcal meningitis, Gilead needs to do everything it can to make good on its promise to provide L-AmB at their access price. In addition, there needs to be a significant effort from countries to prioritise the use of L-AmB and flucytosine, and from manufacturers to start registering and supplying these medicines."

Editor's Note

*Liposomal amphotericin B (L-AMB) *

In September 2018, Gilead announced an "access" price for 116 low- and middle-income countries of US$16.25 per vial of L-AmB, an essential medicine for treatment of fungal infections including first line treatment per WHO guidelines for management of cryptococcal meningitis in people living with HIV. However, Gilead has exclusive agreements with distributors in many countries, allowing L-AmB to be sold for prices as high as $200 per vial in South Africa and $70 per vial in India, and limiting where this access price is available. In countries outside of the territory of the access pricing, such as Brazil, L-AmB costs $373 per vial for cryptococcal meningitis in the public health system, bringing total treatment cost with L-AmB alone to approximately $5000. More than three years later, Gilead has still only provided L-AmB to less than half of the eligible countries at the access price.

While L-AmB has been off patent since 2016, generic manufacturers have been working for years to develop this product, hindered by the fact that Gilead maintains trade secrets and has not been willing to facilitate technology transfer. This allows Gilead to maintain its monopoly and high price on this drug. At the end of 2019, Gilead finally got USFDA approval for a new manufacturing site in California, US, so an end to the usual 4-6 months lead time for orders was anticipated in June 2020. However, this was further delayed until the end of the 2021 as this new facility is also used to produce remdesivir, a treatment for COVID-19, effectively displacing production of L-AmB and causing continued delays. The first generic formulation of L-AmB was approved by the USFDA in December 2021, which could potentially alleviate supply constraints if they register and supply in high-burden countries.

Finally, Gilead has done little to expand access in terms of registration of L-AmB where it is needed most. In the 63 countries where they have registered the drug, only 2 are in sub-Saharan Africa (Ethiopia and South Africa), for example.

Flucytosine (5FC)

Flucytosine is used as part of the first-line WHO-recommended treatment regimen of cryptococcal meningitis, in combination with L-AmB and fluconazole. Despite being an old drug and off patent for many years, the lack of demand meant that there was little interest by generic manufacturers to produce it, with only a few quality-assured sources available that were primarily selling the drug at very high prices in some high-income countries, and neglecting low- and middle-income markets, where demand was lower. As more countries start to update and implement cryptococcal meningitis guidelines and treat more patients, the market demand will increase further. In the past couple of years, 2 new quality-assured generic sources have started to supply the sub-Saharan Africa region, reducing the price to $65 per bottle of 100 tablets from more than $100 for many low- and middle-income countries. In addition, taking flucytosine 4 times per day is difficult for many patients, and ideally development of a sustained-release formulation would serve to improve adherence and treatment for people living with HIV/AIDS.

For interviews, please contact Morag McKenzie at Morag.McKENZIE@berlin.msf.org or +49 172 525 1319

Adblock test (Why?)


MSF responds to new simplified WHO treatment guidelines for cryptococcal meningitis, the number two killer of people living with HIV/AIDS - World - ReliefWeb
Read More

Tuesday, April 19, 2022

COVID-19 vaccination opportunities: week of April 19, 2022 - Public Health Sudbury & Districts

[unable to retrieve full-text content]

  1. COVID-19 vaccination opportunities: week of April 19, 2022  Public Health Sudbury & Districts
  2. BlackburnNews.com - Grey Bruce COVID-19 Vaccination Clinics planned  BlackburnNews.com
  3. COVID-19: Additional vaccine clinics added for Peterborough Public Health region  Global News
  4. GO-VAXX bus visits Collingwood and Wasaga this week  CollingwoodToday.ca
  5. View Full coverage on Google News

COVID-19 vaccination opportunities: week of April 19, 2022 - Public Health Sudbury & Districts
Read More

Doctors suggest new names for low-grade prostate cancer - Victoria News

A cancer diagnosis is scary. Some doctors say it’s time to rename low-grade prostate cancer to eliminate the alarming C-word.

Cancer cells develop in nearly all prostates as men age, and most prostate cancers are harmless. About 34,000 Americans die from prostate cancer annually, but treating the disease can lead to sexual dysfunction and incontinence.

Changing the name could lead more low-risk patients to skip unnecessary surgery and radiation.

“This is the least aggressive, wimpiest form of prostate cancer that is literally incapable of causing symptoms or spreading to other parts of the body,” said University of Chicago Medicine’s Dr. Scott Eggener, who is reviving a debate about how to explain the threat to worried patients.

The words “You have cancer” have a profound effect on patients, Eggener wrote Monday in Journal of Clinical Oncology. He and his co-authors say fear of the disease can cause some patients to overreact and opt for unneeded surgery or radiation.

Others agree. “If you reduce anxiety, you’ll reduce overtreatment,” said Dr. David Penson of Vanderbilt University. “The word ‘cancer,’ it puts an idea in their head: `I have to have this treated.”’

Diagnosis sometimes starts with a PSA blood test, which looks for high levels of a protein that may mean cancer but can also be caused by less serious prostate problems or even vigorous exercise.

When a patient has a suspicious test result, a doctor might recommend a biopsy, which involves taking samples of tissue from the prostate gland. Next, a pathologist looks under a microscope and scores the samples for how abnormal the cells look.

Often, doctors offer patients with the lowest score — Gleason 6 — a way to avoid surgery and radiation: active surveillance, which involves close monitoring but no immediate treatment.

In the U.S., about 60% of low-risk patients choose active surveillance. But they might still worry.

“I would be over the moon if people came up with a new name for Gleason 6 disease,” Penson said. “It will allow a lot of men to sleep better at night.”

But Dr. Joel Nelson of University of Pittsburgh School of Medicine, said dropping the word “cancer” would “misinform patients by telling them there’s nothing wrong. There’s nothing wrong today, but that doesn’t mean we don’t have to keep track of what we’ve discovered.”

Name changes have happened previously in low-risk cancers of the bladder, cervix and thyroid. In breast cancer, there’s an ongoing debate about dropping “carcinoma” from DCIS, or ductal carcinoma in situ.

READ MORE: What do we know about ‘stealth omicron’ so far?

In prostate cancer, the 1960s-era Gleason ranking system has evolved, which is how 6 became the lowest score. Patients may assume it’s a medium score on a scale of 1 to 10. In fact, it’s the lowest on a scale of 6 to 10.

What to call it instead of cancer? Proposals include IDLE for indolent lesion of epithelial origin, or INERRT for indolent neoplasm rarely requiring treatment.

“I don’t really give a hoot what it’s called as long as it’s not called cancer,” Eggener said.

Steve Rienks, a 72-year-old civil engineer in Naperville, Illinois, was diagnosed with Gleason 6 prostate cancer in 2014. He chose active surveillance, and follow-up biopsies in 2017 and 2021 found no evidence of cancer.

Calling it something else would help patients make informed choices, Rienks said, but that’s not enough: Patients need to ask questions until they feel confident.

“It’s about understanding risk,” Rienks said. “I would encourage my fellow males to educate themselves and get additional medical opinions.”

THE ASSOCIATED PRESS

Like us on Facebook and follow us on Twitter 

CancerHealthScience

Adblock test (Why?)


Doctors suggest new names for low-grade prostate cancer - Victoria News
Read More

Do I have COVID-19 or is it just allergies? - Powell River Peak

If you’ve been sneezing or stuffed up for the past few weeks, get ready for the long haul as allergy seasons in British Columbia are getting longer and more intense. 

Allergists warn that global warming is the cause for the longevity of pollen seasons, which makes things complicated for determining if your sniffles might be symptoms of COVID-19 or allergies. 

Thankfully, the experts have some suggestions when trying to determine if it’s a virus or seasonal allergies. 

Glacier Media interviewed Dr. Stephanie Erdle, a clinical instructor in the division of allergy and immunology department of pediatrics at UBC and Dr. Amin Kanani, a clinical associate professor in the division of allergy and immunology at UBC, to find out what British Columbians should know when it comes to the allergy season this year. 

When is allergy season in B.C.?

In British Columbia, we have two large allergy seasons categorized as tree pollen season and grass pollen season. 

Currently, we are going through the tree pollen season. It starts in February and typically settles down by the end of May. 

"But in May grass pollen starts and will go all the way to August,” says Kanani. 

Erdle says the pollen season starts very early in B.C. and pollen counts are going up. 

What are some common spring allergy symptoms?

Itchiness is the biggest giveaway to seasonal allergies, for both eyes and nose.

Is it allergies or COVID?

At first glance, it might be hard to determine what’s causing your sneezing or sniffles, but according to Erdle, there are a few signs to be on the lookout for.

"Although there are some overlapping symptoms, there are some pretty distinct symptoms between the two of them,” she says.

Overlapping symptoms include nasal congestion, stuffy nose and runny nose.

“There are a lot of symptoms that are pretty unique,” she says. "From the allergy side, the number one thing people complain about is itchiness and you don’t usually get that from COVID.”

Itchy and watery eyes are very common for allergies but not for COVID-19 symptoms and "stuffiness” is most likely seen in people with allergies, not COVID-19. 

Kanani agrees the “itch” is often associated with allergies and not viral infections.

"With COVID-19, you can get a stuffy nose and runny nose. But typically with COVID-19 and other viral infections, you don’t get the itch,” he says. 

Typical symptoms people can experience with COVID-19 and not with allergies include a fever, upset stomach, diarrhea and fatigue. 

"With allergies, we don’t usually see fatigue,” he says. 

Another obvious one for the two experts is how long the symptoms last. Allergies will last a few months, whereas if you’re vaccinated, your symptoms if sick with COVID-19 would not last very long. 

What’s the most common allergy? 

The leading cause of tree allergies in Metro Vancouver is alder and birch.

On Vancouver Island, there are a lot of oak tree allergies, according to Kanani. 

"For tree pollen, it is alder and birch in B.C.,” says Erdle. “The next two most common are the whole cedar family and elm.” 

Other common tree allergies in B.C. include ash, maple, mulberry and willow. 

When will pollen go away?

Not until August. 

Tree pollen season lasts until the end of May and grass pollen lasts until August. 

What are the most common allergies kids get?

Erdle sees alder and birch being the two most common tree allergies in children. 

She notes that it is rare to see allergies in children before age three and that they can pop up between age three and 10.

What allergy medication should I take?

Second-generation antihistamines are one recommended way to treat your allergies. 

"The ones that we prefer are Reactine, Claritin, Aerius, Allegra,” says Kanani. “Or prescription ones like Rupall."

What allergy medication should my kids take?

"I tell families, 'Leave the Benadryl and go for one of the non-sedating antihistamines,” says Erdle. “They last longer, they work the same as Benadryl, but they don’t cross into the brain so you don’t get the drowsiness.”

There are some new treatments — like immunotherapy — that can change the immune system through shots.

"I don’t normally recommend this in kids as it’s weekly shots for six months, monthly shots for three to five years, which is not practical for children,” she says. "But there are some newer ones called 'sublingual immunotherapy' that are tablets that go under the tongue.”

Children take these tablets for six to nine months of the year for three years in a row. 

“It can significantly improve symptoms,” she says. 

This type of treatment is available for grass pollen, tree pollen, ragweed pollen and house dust mites.

"I’m seeing younger and younger kids where families are choosing that option,” she says. 

What allergy medication should we avoid?

Both allergists say "second-generation" antihistamines should be used for both kids and adults. 

"The older type we like to avoid because they have a lot more side effects, the main one being sedation and impairment,” says Kanani.

Erdle is advising people not to use Benadryl or similar medication like Tripolon.

"Benadryl is very heavily marketed towards children. We do not recommend Benadryl. It causes a lot of drowsiness, it crosses into the brain and you have to dose it very often,” she says. "Even though it causes drowsiness it really can negatively impact sleep and quality of sleep.”

Why are allergy seasons getting longer?

Trends over the past couple of decades indicate that global warming is having an impact on the allergy seasons in B.C.

"With global warming, we are seeing higher pollen counts and longer pollen seasons so symptoms tend to be worse and that extends into kids as well,” says Erdle. "We are seeing these really long pollen seasons of people having symptoms as early as February going into the fall now." 

Adblock test (Why?)


Do I have COVID-19 or is it just allergies? - Powell River Peak
Read More

Product label changes do not prevent accidental acetaminophen overdoses: Study - Devdiscourse

Changes to acetaminophen product labels did not decrease rates of hospitalization for accidental acetaminophen overdoses, according to a new study. The research was published in 'CMAJ' (Canadian Medical Association Journal).

"We found that changes to acetaminophen labels that communicated the risks of overdose and the presence of acetaminophen in over-the-counter products did not affect rates of hospital admission for accidental acetaminophen overdose, ICU admission for accidental acetaminophen overdose and admission for acetaminophen overdoses involving opioids," wrote Dr Tony Antoniou, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, with coauthors. Acetaminophen is a medication commonly used by millions of people worldwide for pain relief, and although it is generally safe if taken correctly, accidental overdoses can occur because the drug is found in many over-the-counter products for treating pain and the common cold.

In Canada, the percentage of acetaminophen-related injuries related to accidental overdose in Canada increased from 27 per cent in 2006 to 45 per cent in 2011. To increase awareness of potential harm, product label changes were made in Canada in October 2009 to warn of the risk of possible liver damage. In 2016, they were updated with additional labelling for safe dosing and to identify products containing acetaminophen.

However, in this study of more than 12 000 hospital admissions for accidental acetaminophen overdose in 9 provinces and 3 territories in Canada between 2004 and 2020, researchers found there was no impact from the updated labelling on admissions. The authors suggest these findings have several implications for public health.

"Because of the human and economic burden imparted by accidental acetaminophen overdoses, additional measures for preventing these episodes are required, beyond those that attempt to inform consumers about the potential risks of acetaminophen through product labels and package inserts. This is especially important when considered in light of previous research that showed that fewer than 50 per cent of patients regularly read labelled instructions for use of over-the-counter analgesics, and only 26 per cent read the active ingredients before first use." As well, 4.5 per cent to 6 per cent of patients exceed the maximum daily dosage, perhaps because acetaminophen is found in other cough and cold medications, according to studies from the United Kingdom and the United States.

Suggestions for preventing accidental acetaminophen overdoses include removal of acetaminophen from other nonanalgesic over-the-counter medications, discontinuing opioid-acetaminophen combination products and restricting maximum doses of 325 mg per unit. (ANI)

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Adblock test (Why?)


Product label changes do not prevent accidental acetaminophen overdoses: Study - Devdiscourse
Read More

The Winnipeg Foundation Innovation Fund supports cutting-edge projects - UM Today

February 1, 2024 —  Three interdisciplinary teams from the Rady Faculty of Health Sciences have received $100,000 grants from The Winnipeg...